ClinicalTrials.gg
RecruitingNCT04339270COPD-CARhEUpdated Sep 24, 2026

Chronic Airway Disease, Mucus Rheology and Exacerbations

A Phase 4 interventional study of Azithropycin according to symptoms and Azithromycin according to rheology or symptoms in Chronic Obstructive Pulmonary Disease, sponsored by University Hospital, Montpellier. Recruiting at 3 sites in France. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by University Hospital, Montpellier · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University Hospital, Montpellier.

Planned enrollment
3rd of 11
72 · median 50
Started
2023
the only one that year
Phase 4
Only one
of the 18
Registered
14th of 18
by date

Among the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 4, and was the 14th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier, or all of them as a file.
02

Study summary

The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.

Read the detailed description

The secondary objectives are to compare between the 2 arms:

  • exacerbation number according to their severity (observed throughout the duration of the study);
  • the evolution of the symptoms, the rheology of the sputum, and the pulmonary function (measurements repeated every three months);
  • medication consumption and adverse events (monitored throughout the duration of the study);
  • patient trajectories during follow-up;
  • the overall clinical improvement at the end of the study and the evolution of the quality of life (measurements repeated every 3 months);
  • the change in biomarkers of interest (baseline versus end of study).
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjets between 40 - 85 years (included)
  • Written and signed form
  • Subjects must be able to attend all planned visits and comply with all test procedures
  • Beneficiary of or affiliated with the French social security system
  • Man or woman with for at least 1 year defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and validated by the clinical investigator
  • Optimal treatment according to GOLD class severity C or D recommendations
  • >=3 exacerbation (regardless of severity: mild-moderate-severe) or ≥ 1 severe exacerbations (requiring hospitalization) in the past 12 months
  • Spontaneous or induced sputum production
  • : corrected distance between Q and T waves (QTC) \<450 ms in men, QTC \<470 ms in women
  • Normal audiogram for age or absence of to azithromycin for long course according to Oto-Rhino-Laryngological specialist opinion

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Patients who are prisoners or under other forms of judicial protection
  • Patients under any form of guardianship
  • Participation in another interventional protocol, (current or during the month preceding inclusion)
  • Received azithromycin in the past 3 months
  • Patient whose primary diagnosis is bronchial dilation based on CT scan documentation
  • Known to azithromycin, erythromycin, any other macrolide, ketolide or any of the of the azithromycin-based specialty used
  • Concomitant use of medication with azithromycin (dihydroergotamine, ergotamine, cisapride, colchicine)
  • Other respiratory diseases or associated lung infections
  • Severe hepatic insufficiency and severe cholestasis (a liver biological test will be carried out if clinical suspicion)
  • Renal impairment with \< 40 mL/min
  • Patients with hematological who have undergone hematopoietic stem cell transplantation
  • Patients with galactose intolerance, Lapp lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary disease) due to the presence of lactose in the specialty Zithromax.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Active comparator
    Azithromycin according to symptoms

    Patients randomized to this arm will be prescribed azithromycin in function of their symptoms.

    Drug: Azithropycin according to symptoms

  • Experimental
    Azithromycin according to rheology

    Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology.

    Drug: Azithromycin according to rheology or symptoms

Interventions

  • DrugAzithropycin according to symptoms

    Patients randomized to the "standardized comparator arm" will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers). CASA-Q will be evaluated every 3 months. * If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70. * If the patient has a sputum symptoms score\> 70, management is not changed.

  • DrugAzithromycin according to rheology or symptoms

    Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70). The rheology of mucus will be quantified every 3 months. * If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study. * If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70. * If the patient has a sputum symptoms score\> 70, management is not changed.

06

What researchers measure

Primary outcomes

  1. The main outcome measure is the number of exacerbations over the 12 months of follow-up.

    An exacerbation is defined according to French recommendations as an "acute event characterized by worsening of respiratory symptoms (notably cough, sputum and dyspnea) beyond \[normal\] daily variation and leading to a modification of treatment: either a simple increase in bronchodilators (in this case, a duration greater than 24 hours is required to define an exacerbation) or the addition of another treatment (antibiotic therapy and / or oral corticosteroid therapy)."

    Time frame: 12 months

Secondary outcomes

  1. The number of mild exacerbations throughout follow-up

    A mild exacerbation does not require new additional medicine.

    Time frame: 12 months

  2. The number of moderate exacerbations throughout follow-up

    Moderate exacerbations require antibiotics or oral corticosteroids (but not hospitalization).

    Time frame: 12 months

  3. The number of severe exacerbations throughout follow-up

    Severe exacerbations require hospitalization.

    Time frame: 12 months

  4. COPD Assessment Test (CAT)

    Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

    Time frame: Baseline (Day 0)

  5. COPD Assessment Test (CAT)

    Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

    Time frame: 3 months

  6. COPD Assessment Test (CAT)

    Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

    Time frame: 6 months

  7. COPD Assessment Test (CAT)

    Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

    Time frame: 9 months

  8. COPD Assessment Test (CAT)

    Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.

    Time frame: 12 months

  9. Sino Nasal Outcome Test 22

    The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: Baseline (Day 0)

  10. Sino Nasal Outcome Test 22

    The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: 3 months

  11. Sino Nasal Outcome Test 22

    The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: 6 months

  12. Sino Nasal Outcome Test 22

    The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: 9 months

  13. Sino Nasal Outcome Test 22

    The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: 12 months

  14. Cough and sputum assessment questionnaire (CASA-Q)

    The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

    Time frame: Baseline (Day 0)

  15. Cough and sputum assessment questionnaire (CASA-Q)

    The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

    Time frame: 3 months

  16. Cough and sputum assessment questionnaire (CASA-Q)

    The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

    Time frame: 6 months

  17. Cough and sputum assessment questionnaire (CASA-Q)

    The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

    Time frame: 9 months

  18. Cough and sputum assessment questionnaire (CASA-Q)

    The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.

    Time frame: 12 months

  19. Visual analogue scale for dyspnea

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

    Time frame: Baseline (Day 0)

  20. Visual analogue scale for dyspnea

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

    Time frame: 3 months

  21. Visual analogue scale for dyspnea

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

    Time frame: 6 months

  22. Visual analogue scale for dyspnea

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

    Time frame: 9 months

  23. Visual analogue scale for dyspnea

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).

    Time frame: 12 months

  24. Visual analogue scale for coughing

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

    Time frame: Baseline (Day 0)

  25. Visual analogue scale for coughing

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

    Time frame: 3 months

  26. Visual analogue scale for coughing

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

    Time frame: 6 months

  27. Visual analogue scale for coughing

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

    Time frame: 9 months

  28. Visual analogue scale for coughing

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).

    Time frame: 12 months

  29. Visual analogue scale for sputum production

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

    Time frame: Baseline (Day 0)

  30. Visual analogue scale for sputum production

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

    Time frame: 3 months

  31. Visual analogue scale for sputum production

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

    Time frame: 6 months

  32. Visual analogue scale for sputum production

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

    Time frame: 9 months

  33. Visual analogue scale for sputum production

    A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).

    Time frame: 12 months

  34. Rheology: modulus of elasticity of mucus (G ')

    Time frame: Baseline (Day 0)

  35. Rheology: modulus of elasticity of mucus (G ')

    Time frame: 3 months

  36. Rheology: modulus of elasticity of mucus (G ')

    Time frame: 6 months

  37. Rheology: modulus of elasticity of mucus (G ')

    Time frame: 9 months

  38. Rheology: modulus of elasticity of mucus (G ')

    Time frame: 12 months

  39. Rheology: the viscous module (G '')

    Time frame: Baseline (Day 0)

  40. Rheology: the viscous module (G '')

    Time frame: 3 months

  41. Rheology: the viscous module (G '')

    Time frame: 6 months

  42. Rheology: the viscous module (G '')

    Time frame: 9 months

  43. Rheology: the viscous module (G '')

    Time frame: 12 months

  44. Rheology: The ratio G '' / G '

    Time frame: Baseline (Day 0)

  45. Rheology: The ratio G '' / G '

    Time frame: 3 months

  46. Rheology: The ratio G '' / G '

    Time frame: 6 months

  47. Rheology: The ratio G '' / G '

    Time frame: 9 months

  48. Rheology: The ratio G '' / G '

    Time frame: 12 months

  49. Rheology: the critical constraint (tau-C).

    Time frame: Baseline (Day 0)

  50. Rheology: the critical constraint (tau-C).

    Time frame: 3 months

  51. Rheology: the critical constraint (tau-C).

    Time frame: 6 months

  52. Rheology: the critical constraint (tau-C).

    Time frame: 9 months

  53. Rheology: the critical constraint (tau-C).

    Time frame: 12 months

  54. Spirometry: forced expiratory volume in 1 minute (FEV1)

    Time frame: Baseline (day 0)

  55. Spirometry: forced expiratory volume in 1 minute (FEV1)

    Time frame: 3 months

  56. Spirometry: forced expiratory volume in 1 minute (FEV1)

    Time frame: 6 months

  57. Spirometry: forced expiratory volume in 1 minute (FEV1)

    Time frame: 9 months

  58. Spirometry: forced expiratory volume in 1 minute (FEV1)

    Time frame: 12 months

  59. Spirometry: forced vital capacity (FVC)

    Time frame: Baseline (day 0)

  60. Spirometry: forced vital capacity (FVC)

    Time frame: 3 months

  61. Spirometry: forced vital capacity (FVC)

    Time frame: 6 months

  62. Spirometry: forced vital capacity (FVC)

    Time frame: 9 months

  63. Spirometry: forced vital capacity (FVC)

    Time frame: 12 months

  64. Spirometry: FEV1/FVC

    Time frame: Baseline (day 0)

  65. Spirometry: FEV1/FVC

    Time frame: 3 months

  66. Spirometry: FEV1/FVC

    Time frame: 6 months

  67. Spirometry: FEV1/FVC

    Time frame: 9 months

  68. Spirometry: FEV1/FVC

    Time frame: 12 months

  69. Plethysmography for lung volumes: residual volume (RV)

    Time frame: Baseline (day 0)

  70. Plethysmography for lung volumes: residual volume (RV)

    Time frame: 3 months

  71. Plethysmography for lung volumes: residual volume (RV)

    Time frame: 6 months

  72. Plethysmography for lung volumes: residual volume (RV)

    Time frame: 9 months

  73. Plethysmography for lung volumes: residual volume (RV)

    Time frame: 12 months

  74. Plethysmography for lung volumes: functional residual capacity (FRC)

    Time frame: Baseline (day 0)

  75. Plethysmography for lung volumes: functional residual capacity (FRC)

    Time frame: 3 months

  76. Plethysmography for lung volumes: functional residual capacity (FRC)

    Time frame: 6 months

  77. Plethysmography for lung volumes: functional residual capacity (FRC)

    Time frame: 9 months

  78. Plethysmography for lung volumes: functional residual capacity (FRC)

    Time frame: 12 months

  79. Plethysmography for lung volumes: total lung capacity (TLC)

    Time frame: Baseline (day 0)

  80. Plethysmography for lung volumes: total lung capacity (TLC)

    Time frame: 3 months

  81. Plethysmography for lung volumes: total lung capacity (TLC)

    Time frame: 6 months

  82. Plethysmography for lung volumes: total lung capacity (TLC)

    Time frame: 9 months

  83. Plethysmography for lung volumes: total lung capacity (TLC)

    Time frame: 12 months

  84. Plethysmography for lung volumes: RV/TLC

    Time frame: Baseline (day 0)

  85. Plethysmography for lung volumes: RV/TLC

    Time frame: 3 months

  86. Plethysmography for lung volumes: RV/TLC

    Time frame: 6 months

  87. Plethysmography for lung volumes: RV/TLC

    Time frame: 9 months

  88. Plethysmography for lung volumes: RV/TLC

    Time frame: 12 months

  89. Drug consumption throughout the study.

    Time frame: 12 months

  90. The number of adverse events will be recorded throughout the study.

    Time frame: 12 months

  91. Episodes of exacerbation throughout the study

    For each exacerbation, the beginning and end dates will be recorded.

    Time frame: 12 months

  92. Episodes of hospitalization throughout the study

    For each hospitalization, the beginning and end dates will be recorded.

    Time frame: 12 months

  93. Clinical improvement

    Clinical improvement is scored via a point system from 0 to 3 at the end of the study. The points are added-up as follows: * 1 point: no more than one exacerbation without hospitalization during the 52 weeks of follow-up; * 1 point: gain \> 100mL in pre-bronchodilator FEV1 at the 52nd week compared to the baseline state; * 1 point: variation of the CAT score during the 52 weeks of observation \> 2.

    Time frame: 12 months

  94. Medical outcomes study 36-Item Short Form Survey (SF-36)

    The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: Baseline (day 0)

  95. Medical outcomes study 36-Item Short Form Survey (SF-36)

    The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: 3 months

  96. Medical outcomes study 36-Item Short Form Survey (SF-36)

    The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: 6 months

  97. Medical outcomes study 36-Item Short Form Survey (SF-36)

    The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: 9 months

  98. Medical outcomes study 36-Item Short Form Survey (SF-36)

    The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: 12 months

  99. EQ-5D-5L

    In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

    Time frame: Baseline (day 0)

  100. EQ-5D-5L

    In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

    Time frame: 3 months

  101. EQ-5D-5L

    In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

    Time frame: 6 months

  102. EQ-5D-5L

    In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

    Time frame: 9 months

  103. EQ-5D-5L

    In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.

    Time frame: 12 months

  104. St-George's Respiratory Questionnaire

    Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: Baseline (day 0)

  105. St-George's Respiratory Questionnaire

    Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: 3 months

  106. St-George's Respiratory Questionnaire

    Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: 6 months

  107. St-George's Respiratory Questionnaire

    Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: 9 months

  108. St-George's Respiratory Questionnaire

    Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: 12 months

  109. Blood cell differential: neutrophil levels

    A complete blood cell differential will be taken, including neutrophilia and eosinophilia.

    Time frame: Baseline (day 0)

  110. Blood cell differential: eosinophil levels

    A complete blood cell differential will be taken, including neutrophilia and eosinophilia.

    Time frame: Baseline (day 0)

  111. Blood cell differential: neutrophil levels

    A complete blood cell differential will be taken, including neutrophilia and eosinophilia.

    Time frame: 12 months

  112. Blood cell differential: eosinophil levels

    A complete blood cell differential will be taken, including neutrophilia and eosinophilia.

    Time frame: 12 months

  113. Serum Club cell secretory protein

    Time frame: Baseline (day 0)

  114. Serum Club cell secretory protein

    Time frame: 12 months

  115. Sputum bacteriology

    Time frame: Baseline (day 0)

  116. Sputum bacteriology

    Time frame: 12 months

07

Study locations

3 of 3 sites recruiting
  • University Hospitals of Bordeaux
    Bordeaux, France
    Recruiting
    • Maéva Zysman, MD, PhD · Principal investigator
  • University Hospitals of Montpellier
    Montpellier, 34925, France
    Recruiting
    • Jérémy Charriot, MD · Principal investigator
    • Arnaud Bourdin, MD, PhD · Sub investigator
    • Anne-Sophie Gamez, MD · Sub investigator
    • Jean Romain, MD · Sub investigator
  • University Hospitals of Toulouse
    Toulouse, France
    Recruiting
    • Laurent Guilleminault, MD · Principal investigator
    • Alain Didier, MD, PhD · Sub investigator
    • Danielle Brouquieres, MD · Sub investigator
    • Nicolas Guibert, MD · Sub investigator
    • Sandrine Pontier Marchandise, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The general goal is to make the study data available to interested researchers as well as to provide proof of transparency for the study. Data (and an accompanying data dictionary) will be de-identified and potentially further cleaned or aggregated as the investigators deem necessary to protect participant anonymity. Data will be made available to persons who address a reasonable request to the study director and fulfil the requirements stipulated by the French CNIL (Commission Nationale de l'Informatique et des Libertés : https://www.cnil.fr/professionnel).

Time frame: As close to "real time" as possible, the following supporting information will be made public: Study Protocol (to be published in an appropriate journal). Statistical Analysis Plan Participant Information materials Analytic code These will be posted and registered on osf.io and/or clinicaltrials.gov (if not published). Datasets can be requested after the publication process has been completed.

Access criteria: The conditions under which members of the public will be granted access to datasets are: The data will be used/examined in a not-for-profit manner; The data will not be used in an attempt to identify a participant or group of participants; The user does not work for a private insurance company; The data will not be used in support of any kind of private insurance policy or health penalties; The data will be used/examined for the advancement of science/teaching while respecting participant/patient privacy and rights; The user will state why they wish to access the data. The appropriate CNIL approval has been obtained by the user.

Data sharing details ↗ · osf.io

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2027, 48 months after the start.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 48 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2020
First posted
Apr 9, 2020
StartActual
Feb 3, 2023
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04339270
Collaborators
Rheonova
Responsible party
Sponsor
First posted
Apr 9, 2020
Start date
Feb 3, 2023
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 24, 2026

Study contacts

Jérémy Charriot, MD
Contact
j-charriot@chu-montpellier.fr
04 67 33 67 33
Arnaud BOURDIN, MD
Contact
a-bourdin@chu-montpellier.fr
04 67 33 67 33
Jérémy Charriot, MD
study director · University Hospital, Montpellier

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion